Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RONIN: Negr1 in Major Depression
NCT06131268Phase 4Unknown
- Sponsor
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
- Start
- Mar 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of venlafaxine in major depressive disorder (MDD) (3 arms), sponsored by Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. Primary endpoint: Change in Negr1 gene expression in whole blood at 4 weeks. Status: unknown.
02
Drugs
venlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06131268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06131268.